NOVARTIS
🇨🇭Switzerland
- Country
- 🇨🇭Switzerland
- Ownership
- Public, Private
- Established
- 1996-01-01
- Employees
- 76K
- Market Cap
- $242.6B
Pharmacokinetics (PK) and Metabolism of FTY720 in Patients With Severe Renal Impairment and Healthy Matched Subjects.
- First Posted Date
- 2008-08-11
- Last Posted Date
- 2020-12-09
- Lead Sponsor
- Novartis
- Target Recruit Count
- 18
- Registration Number
- NCT00731523
- Locations
- 🇷🇺
Novartis Investigator Site, Moscow, Russian Federation
Albinterferon Alfa 2b Single Dose in Japanese Chronic Hepatitis C Patients
- First Posted Date
- 2008-07-30
- Last Posted Date
- 2020-12-08
- Lead Sponsor
- Novartis
- Target Recruit Count
- 30
- Registration Number
- NCT00724776
- Locations
- 🇯🇵
Novartis Pharmaceuticals, Japan, Tokyo, Japan
Efficacy, Safety and Tolerability of AFQ056 in Fragile X Patients
- First Posted Date
- 2008-07-18
- Last Posted Date
- 2020-02-11
- Lead Sponsor
- Novartis
- Target Recruit Count
- 30
- Registration Number
- NCT00718341
- Locations
- 🇨🇭
Novartis Investigator Site, Lausanne, Switzerland
Evaluation of Safety and Efficacy of Artemether-Lumefantrine Tablets in African Infants and Children With Uncomplicated P. Falciparum Malaria
- First Posted Date
- 2008-07-03
- Last Posted Date
- 2008-07-03
- Lead Sponsor
- Novartis
- Target Recruit Count
- 310
- Registration Number
- NCT00709969
- Locations
- 🇰🇪
Kemri-Wellcome Trust Programme, Kilifi, Kenya
🇳🇬University College Hospital Malaria Research Laboratories Institute for Advance Medical Research and Training, Ibadan, Nigeria
🇹🇿Muhimbili University College of Health Sciences Department of Parasitology and Medical Entomology, Box 65011, Dar es Salaam, Tanzania
Efficacy and Safety of Aliskiren 75 mg, 150 mg, and 300 mg in Elderly Patients With Essential Hypertension When Given With a Light Meal in a 8 Week Placebo-controlled Study
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-06-27
- Last Posted Date
- 2011-06-28
- Lead Sponsor
- Novartis
- Target Recruit Count
- 756
- Registration Number
- NCT00706134
- Locations
- 🇸🇰
Investigative Site, Bratislava, Slovakia
Efficacy and Safety of the Combination Aliskiren (300 mg) and Hydrochlorothiazide (25mg) to Aliskiren (300mg) Monotherapy in Patients With Staged II Hypertension
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-06-26
- Last Posted Date
- 2011-05-30
- Lead Sponsor
- Novartis
- Target Recruit Count
- 688
- Registration Number
- NCT00705575
- Locations
- 🇹🇷
Investigative Site, Ankara, Turkey
Pharmacologic Effects of Darifenacin and Tolterodine on Cardiovascular Parameters in Healthy Subjects
- First Posted Date
- 2008-06-23
- Last Posted Date
- 2012-08-02
- Lead Sponsor
- Novartis
- Target Recruit Count
- 117
- Registration Number
- NCT00703703
- Locations
- 🇺🇸
Investigative Site, Morgantown, West Virginia, United States
Efficacy/Safety of Lansoprazole in Patients With Frequent Nighttime Heartburn
- First Posted Date
- 2008-06-19
- Last Posted Date
- 2010-01-15
- Lead Sponsor
- Novartis
- Target Recruit Count
- 852
- Registration Number
- NCT00701259
- Locations
- 🇺🇸
Not applicable - enrollment complete, Parsippany, New Jersey, United States
Efficacy, Safety and Tolerability of DNK333 (25 and 100 mg Bid) in Women With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)
- First Posted Date
- 2008-06-17
- Last Posted Date
- 2008-06-17
- Lead Sponsor
- Novartis
- Target Recruit Count
- 135
- Registration Number
- NCT00699166
Evalution of Immunogenicity, Safety and Booster Response of a Rabies Vaccine Administered Concomitantly With Japanese Encephalitis Vaccine in Toddlers
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-06-10
- Last Posted Date
- 2008-06-10
- Lead Sponsor
- Novartis
- Target Recruit Count
- 200
- Registration Number
- NCT00694460
- Locations
- 🇹🇭
Tropical Medicine, Mahidol University, Bangkok, Thailand
© Copyright 2024. All Rights Reserved by MedPath